Apellis Pharma…
ProfileJobs

Apellis Pharmaceuticals

Suggest Edit
    • Healthcarebiotechdrug developmentpharma
    Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
    Market capitalization(2018-12-14)
    $1.1 B

    Employee Rating

    0More
    TypePublic
    HQCrestwood, US
    Founded2008
    Size (employees)32 (est)
    Websiteapellis.com
    Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Apellis Pharmaceuticals

    Cedric Francois

    Cedric Francois

    President and CEO
    Mike Yeadon

    Mike Yeadon

    Chief Scientific Officer
    Pascal Deschatelets

    Pascal Deschatelets

    Founder & Chief Operating Officer
    Show more

    Apellis Pharmaceuticals Office Locations

    Apellis Pharmaceuticals has offices in Crestwood, Waltham, Cambridge and San Francisco
    Crestwood, US (HQ)
    6400 Westwind Way
    Cambridge, US
    1218 Massachusetts Ave
    San Francisco, US
    300 41 Grant Ave
    Waltham, US
    200 5th Ave
    Show all (4)
    Report incorrect company information

    Apellis Pharmaceuticals Financials and Metrics

    Apellis Pharmaceuticals Revenue

    USD

    EBIT (Q2, 2018)

    		(33.5m)

    Market capitalization (14-Dec-2018)

    		1.1b

    Closing stock price (14-Dec-2018)

    		18.7

    Cash (30-Jun-2018)

    		253.8m
    Apellis Pharmaceuticals's current market capitalization is $1.1 b.
    Annual
    USDFY, 2017

    Cash

    		175.6m

    Current Assets

    		182.0m

    Total Assets

    		182.1m

    Accounts Payable

    		3.7m
    Quarterly
    USDQ3, 2017Q1, 2018Q2, 2018

    Cash

    		13.1m152.9m253.8m

    Current Assets

    		19.0m163.1m266.7m

    Total Assets

    		19.1m163.2m266.8m

    Accounts Payable

    		4.0m4.6m5.1m
    show all
    Annual
    USDFY, 2017

    Net Income

    		(51.0m)

    Accounts Payable

    		932.3k

    Cash From Operating Activities

    		(46.6m)

    Cash From Financing Activities

    		197.4m
    Quarterly
    USDQ3, 2017Q1, 2018Q2, 2018

    Net Income

    		(32.8m)(21.7m)(55.1m)

    Accounts Payable

    		1.5m921.8k1.5m

    Cash From Operating Activities

    		(31.1m)(22.9m)(53.6m)

    Cash From Financing Activities

    		19.3m222.7k131.8m
    show all
    USDY, 2018

    Financial Leverage

    		1.2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    MyoKardia
    Healthcare - Public
    Athersys
    Healthcare - Public
    Ironwood Pharmaceuticals
    Healthcare - Public
    Biogen
    Healthcare - Public
    Compare competitors

    Apellis Pharmaceuticals Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Apellis Pharmaceuticals News and Updates

    December 03, 2018

    Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH

    -  New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA)
    December 02, 2018

    Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH

    CRESTWOOD, Ky., and WALTHAM, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced i…
    November 13, 2018

    Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results

    - Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) -
    November 01, 2018

    Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting

    CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today th…
    September 04, 2018

    Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy

    PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™
    July 31, 2018

    Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results

    - Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 -
    Show more
    Report incorrect company information

    Apellis Pharmaceuticals Company Life and Culture

    Report incorrect company information
    Download PDF

     Apellis Pharmaceuticals Frequently Asked Questions

    • When was Apellis Pharmaceuticals founded?

      Apellis Pharmaceuticals was founded in 2008.

    • Who are Apellis Pharmaceuticals key executives?

      Apellis Pharmaceuticals's key executives are Cedric Francois, Mike Yeadon and Pascal Deschatelets.

    • How many employees does Apellis Pharmaceuticals have?

      Apellis Pharmaceuticals has 32 employees.

    • Who are Apellis Pharmaceuticals competitors?

      Competitors of Apellis Pharmaceuticals include MyoKardia, Athersys and Ironwood Pharmaceuticals.

    • Where is Apellis Pharmaceuticals headquarters?

      Apellis Pharmaceuticals headquarters is located at 6400 Westwind Way, Crestwood.

    • Where are Apellis Pharmaceuticals offices?

      Apellis Pharmaceuticals has offices in Crestwood, Waltham, Cambridge and San Francisco.

    • How many offices does Apellis Pharmaceuticals have?

      Apellis Pharmaceuticals has 4 offices.